Emyria S3 CBD trial ‘on hold’ as firm stresses need to focus on revenue by Steve Jones February 7, 2024February 7, 2024 Emyria has said it must focus on revenue generation rather than registering a low-dose CBD product […]
Financial results: Bod Science; Zelira Therapeutics; Emyria; Epsilon Healthcare; Elixinol; MGC Pharma by Steve Jones August 1, 2023April 30, 2024
Emyria eyes US market with launch of high-dose CBD capsule by Steve Jones April 24, 2023April 30, 2024
Emyria strikes commercial deal with Aspen for over-the-counter product by Steve Jones April 4, 2023April 30, 2024
Company news: Emyria; Ananda Wellness; InhaleRx; Cann Global; HFA by Steve Jones September 28, 2022April 29, 2024
Emyria posts A$7m loss but insists 2023 will be ‘momentous’ by Steve Jones August 30, 2022April 29, 2024
Cannabis risks becoming a ‘borderline supplement’ unless it evolves, warns Emyria chief by Steve Jones August 18, 2022April 29, 2024
Company news: MGC Pharma; Emyria; Incannex, IvyMed Clinic by Steve Jones August 17, 2022April 29, 2024
Company news: Emyria; Cann Group; Creso Pharma; Cronos; MGC Pharma by Martin Lane April 14, 2022April 29, 2024
